Target
NTRK
2 products, 3 indications
Indications
ROS1-rearranged NSCLC (1 products)
NSCLC with EGFR exon 20 insertion mutations (1 products)
EGFR ex20ins-mutant NSCLC (1 products)
Loading...
1 drug
26 abstracts
Abstract
Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions.Org: Roche Products Ltd., Genentech, Memorial Sloan Kettering Cancer Center, Hopp Children’s Cancer Center Heidelberg (KiTZ), Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
Abstract
Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC).Org: Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Seoul National University Hospital, Cancer Research Institute and National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Chrestos Concept GmbH & Co. KG,
Abstract
Immune infiltrate characterization and differential gene expression by RNA-sequencing analysis in patients with oncogene-addicted NSCLC with early progression under targeted therapy.Org: Genomic Platform and Biobank, AMMICa UAR3655/US23, Gustave Roussy, Cancer Campus,
Abstract
A real-world study on biomarker retesting among patients with non-small cell lung cancer and disparity in outcomes.Org: AbbVie Inc., North Chicago, IL, Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).Org: Nashville, OneOncology, TN, South San Francisco, Genentech,
Abstract
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).Org: Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, RI-MUHC,
Abstract
Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for metastatic colorectal cancer patients in the VA’s National Precision Oncology Program (NPOP).Org: Center for Innovations in Quality Effectiveness and Safety, Houston, TX, VA Boston Healthcare System, Boston, MA, Baylor College of Medicine,
Abstract
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.Org: NeoGenomics Ltd, Cambridge, United Kingdom, Medipole Lyon Villeurbanne, Villeurbanne, France, Infirmerie Protestante, Caluire Et Cuire, France, Institut de Cancérologie Strasbourg Europe ICANS, Strasbourg, France,
Abstract
Advancing individualized care in advanced gastroesophageal cancers (GEC): A quality improvement initiative.Org: Massachusetts General Hospital, PRIME Education LLC,
Abstract
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.Org: EMD Serono Research & Development Institute, Genesis Research, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center,
Abstract
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Tempus Labs, Inc., David Geffen School of Medicine UCLA, Ohio State University Comprehensive Cancer Center,
Abstract
An application of extrapolating clinical data from single-arm trials to assess comparative effectiveness.Org: University of Pittsburgh, Pittsburgh, PA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Curta Health, Bayer US LLC, CHOICE Institute, School of Pharmacy, University of Washington,
Abstract
Real-world analysis of commercially insured and Medicare Advantage patients with advanced cancer and rates of molecular testing.Org: Optum Labs, Eden Prairie, MN, Illumina, Inc., San Diego State University Department of Biology, San Diego, CA,
Abstract
Genomic biomarker testing and treatment in advanced NSCLC: Practice patterns and barriers in a global survey of oncology point-of-care mobile app users.Org: Siyemi Learning, ONCOassist, Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom,
Abstract
Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.Org: Integra Connect PrecisionQ, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists and Research Institute, Ocala, FL, Thermo Fisher Scientific,
Abstract
Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).Org: Yonsei University College of Medicine, Seoul, Korea, Republic of (South), Taipei Medical University Hospital, Taipei City, Taiwan, City of Hope Comprehensive Cancer Center,
Abstract
Assessment of genomic profiling in patients with colorectal cancer treated in community oncology practices.Org: Compass Oncology, Ontada,
Abstract
Influence of follow-up time on outcome of children and adolescents with atypical Spitz tumor/Spitz melanoma (AST/SM): Results from the MACMEL registry.Org: St Jude Childrens Research Hospital, St. Jude Children's Research Hospital, Department of Oncology, St. Jude Children's Research Hospital,
Abstract
Gaps and factors in patient awareness of biomarker test timing and purpose in non-small cell lung cancer (NSCLC): Baseline assessment for implementation of 4R Oncology model.Org: Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Center for Business Models on Healthcare, Glencoe, IL, Johns Hopkins Hospital, Baltimore, MD, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, Emory University Hospital, Atlanta, GA, Emory University, Atlanta, GA, Grady Memorial Hospital, Atlanta, GA, SOMC Cancer Center, Portsmouth, OH, SOUTHERN OHIO MEDICAL CENTER, Portsmouth, OH, Southern Ohio Medical Center, Portsmouth, OH, Northwestern Memorial Hospital, Chicago, IL, Northwestern University, Chicago, IL, Wake Forest School of Medicine, Winston-Salem, NC, LUNGevity Foundation, Bethesda, MD, Association of Community Cancer Centers, Rockville, MD, Association of Community Cancer Centers (ACCC), Rockville, MD, Center for Business Models in Healthcare, Glencoe, IL,
Abstract
Examining molecular testing practices and targeted therapy use in advanced/metastatic non-small cell lung cancer (mNSCLC): A quality improvement initiative across ten community cancer centers.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, PRIME Education LLC,
Abstract
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.Org: US Oncology Research/New York Oncology Hematology, Albany, NY, US Oncology Research/Oncology Associates of Oregon P.C., Eugene, OR, US Oncology Research/Virginia Oncology Associates, Newport News, VA, US Oncology Research/Oncology Hematology Care, Inc., The Woodlands, TX, US Oncology Research/Virginia Cancer Specialists, Fairfax, VA,
Abstract
Patient characteristics, treatment patterns, and clinical outcomes among patients with de novo advanced or metastatic (stage IIIB–IV) non-small cell lung cancer in a real-world setting.Org: EMD Serono Research & Development Institute, Rockland, MA, Genesis Research, Hoboken, NJ, Memorial Sloan Kettering Cancer Center,
Abstract
Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis.Org: Federal University of Pelotas, Pelotas, Brazil, Brazil, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil,
Abstract
Does the landscape of comprehensive genomic profiling in patients with advanced stage lung cancer in India differ from data from the western countries.Org: Fortis Cancer Institute, New Delhi, India, Fortis Cancer Institute, Bangalore Karnataka, India, Fortis Cancer Institute, Gurgaon, Haryana, India, Fortis Cancer Institute, Delhi, India, Fortis Hospital and research centre, New Delhi, India,
Abstract
Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project.Org: University of Modena and Reggio Emilia, Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori (IRST), Molecular Pathology Laboratory, Program Clinical and Experimental Medicine,
Abstract
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study.Org: University of Verona, Oncology Section, Azienda Ospedaliera Universitaria Integrata di Verona, Ospedale San Bortolo Azienda ULSS8 Berica - Distretto Est, Santa Chiara Hospital, Trento, Italy, Policlinico Universitario Gaspare Rodolico,
Drug
taletrectinib